Skip to main content

Identification, presentation and delivery of epitopes for development of novel vaccine for cytomegalovirus infections

Objective

The EPI-PEP-VAC consortium will use cutting-edge research and the most advanced technologies to elucidate the structural, biochemical and cellular basis of the immune response to exogenously delivered peptide epitopes, with the central objective of defining basic rules for the selection and optimisation of peptide vaccine candidates. The research will be focused on a pathogen of major health and socio-economical importance in the EU, namely human cytomegalovirus (HCMV). Novel strategies, technologies and read-out assays will be developed for peptide definition, modelling and screening to achieve optimal peptide performance. Animal models and ex-vivo models for follow-up will be developed and used for establishment of diagnostic tools and to optimise delivery system and immunization route of peptide vaccines.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

WEIZMANN INSTITUTE OF SCIENCE
Address
Herzel Street 2
76100 Rehovot
Israel

Participants (8)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Parc Scientifique Et Technologique De Luminy
13288 Marseille
IMMUNOTECH SA
France
Address
Av. De Lattre De Tassigny 130
13009 Marseille
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Parc Scientifique De Luminy
13288 Marseille
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Bd Fleming 1
25000 Besancon
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Germany
Address
Stuebeweg 51
79108 Freiburg (In Breisgau)
NATIONAL RESEARCH COUNCIL OF ITALY
Italy
Address
Via Guglielmo Marconi 10
80125 Napoli
THE UNIVERSITY OF TUEBINGEN
Germany
Address
Auf Der Morgenstelle, 15
72076 Tuebingen
UNIVERSIT DEGLI STUDI DI SIENA
Italy
Address
Via Aldo Moro 2
53100 Siena